Intellia Therapeutics Announced Single Dose Of Ntla-2002 Led To A 98% Mean Reduction In Monthly Hereditary Angioedema Attack Rate, With An Average Follow-up Of Over 20 Months Across All Patients
Portfolio Pulse from Charles Gross
Intellia Therapeutics announced that a single dose of NTLA-2002 led to a 98% mean reduction in monthly hereditary angioedema (HAE) attack rates, with an average follow-up of over 20 months. The data, presented at the EAACI Congress 2024, showed that 8 out of 10 patients remained attack-free and all patients who discontinued prophylaxis treatment remained free of chronic prophylaxis. The therapy demonstrated a favorable safety and tolerability profile.
June 02, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intellia Therapeutics' NTLA-2002 demonstrated a 98% reduction in HAE attack rates with favorable safety and tolerability, potentially positioning it as a functional cure for HAE. This positive data could boost investor confidence and drive the stock price up.
The significant reduction in HAE attack rates and the favorable safety profile of NTLA-2002 are likely to increase investor confidence in Intellia Therapeutics. The potential of NTLA-2002 to be a functional cure for HAE could lead to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100